Alzheimer's disease
Cognitive testing by telephone in elderly individuals is generally as effective as in-person testing, according to a new study by Effie M. Mitsis, PhD, Assistant Professor of Psychiatry at Mount Sinai School of Medicine and part of Mount Sinai's Alzheimer's Disease Research Center. The study will appear in the International Journal of Geriatric Psychiatry.
UPTON, NY -- How much difference can a tenth of a nanometer make? When it comes to figuring out how proteins work, an improvement in resolution of that miniscule amount can mean the difference between seeing where atoms are and understanding how they interact.
HOUSTON -- (Sept. 9, 2009) -- Ever wonder why former smokers miss lighting up most when they are in a bar or after a meal with friends?
Amsterdam, September 8, 2009 -- Researchers at the Institute of Biochemistry and Molecular Biology I of the Heinrich-Heine University, Düsseldorf, Germany, investigated the relationship between fruit and vegetable intake, plasma antioxidant micronutrient status and cognitive performance in healthy subjects aged 45 to 102 years.
WEST LAFAYETTE, Ind. - The polyphenols found in red wine are thought to help prevent Alzheimer's disease, and new research from Purdue University and Mount Sinai School of Medicine has shown that some of those compounds in fact reach the brain.
NEW YORK - In the first functional magnetic resonance imaging (fMRI) study of its kind, neurologists and psychiatrists at Columbia University have identified an area of the
brain involved in the earliest stages of schizophrenia and related psychotic disorders.
ST. PAUL, Minn. -- Getting a cold, stomach bug or other infection may lead to increased memory loss in people with Alzheimer's disease, according to research published in the September 8, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.
NEW YORK - A drug now used to treat cancer may also be able to restore memory deficits in patients with Alzheimer's disease, according to a new study conducted by scientists at Columbia University Medical Center, which appeared in the September issue of The Journal of Alzheimer's Disease: Volume 18:1.
St. Louis, Sept. 6, 2009 -- An international team of scientists has identified two more genetic risk factors for Alzheimer's disease. The findings are reported in the online edition of the journal Nature Genetics.
DURHAM, N.C. -- Sticking with what you know often comes at the price of learning about more favorable alternatives.
Managing this trade-off is easy for many, but not for those with conditions such as Alzheimer's disease or obsessive-compulsive disorder who are trapped in simple routines.
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope.
Researchers at the Yerkes National Primate Research Center, Emory University, have demonstrated that prairie voles may be a useful model in understanding the neurochemistry of social behavior. By influencing early social experience in prairie voles, researchers hope to gain greater insight into what aspects of early social experience drive diversity in adult social behavior.
Scientists have developed a new molecular sensor that can reveal the amount of zinc in cells, which could tell us more about a number of diseases, including type 2 diabetes.
CAMBRIDGE, Mass. -- Researchers at MIT's Picower Institute for Learning and Memory have found that rats use a mental instant replay of their actions to help them decide what to do next, shedding new light on how animals and humans learn and remember.
The work will appear in the Aug. 27 issue of the journal Neuron.
BEDFORD, MA ?August, 24, 2009 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.
